-
Something wrong with this record ?
High PD-L1 Expression Predicts for Worse Outcome of Leukemia Patients with Concomitant NPM1 and FLT3 Mutations
B. Brodská, P. Otevřelová, C. Šálek, O. Fuchs, Z. Gašová, K. Kuželová,
Language English Country Switzerland
Document type Journal Article
Grant support
grant No 16-30268A and project for conceptual development of the research organization No 00023736.
Ministerstvo Zdravotnictví Ceské Republiky
NV16-30268A
MZ0
CEP Register
Digital library NLK
Full text - Article
NLK
Free Medical Journals
from 2000
Freely Accessible Science Journals
from 2000
PubMed Central
from 2007
Europe PubMed Central
from 2007
ProQuest Central
from 2000-03-01
Open Access Digital Library
from 2000-01-01
Open Access Digital Library
from 2007-01-01
Health & Medicine (ProQuest)
from 2000-03-01
ROAD: Directory of Open Access Scholarly Resources
from 2000
PubMed
31185600
DOI
10.3390/ijms20112823
Knihovny.cz E-resources
- MeSH
- Leukemia, Myeloid, Acute blood genetics MeSH
- B7-H1 Antigen blood genetics metabolism MeSH
- Nuclear Proteins genetics MeSH
- Humans MeSH
- RNA, Messenger genetics metabolism MeSH
- Mutation MeSH
- Biomarkers, Tumor blood genetics metabolism MeSH
- fms-Like Tyrosine Kinase 3 genetics MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
Compared to solid tumors, the role of PD-L1 in hematological malignancies is less explored, and the knowledge in this area is mostly limited to lymphomas. However, several studies indicated that PD-L1 is also overexpressed in myeloid malignancies. Successful treatment of the acute myeloid leukemia (AML) is likely associated with elimination of the residual disease by the immune system, and possible involvement of PD-L1 in this process remains to be elucidated. We analyzed PD-L1 expression on AML primary cells by flow cytometry and, in parallel, transcript levels were determined for the transcription variants v1 and v2. The ratio of v1/v2 cDNA correlated with the surface protein amount, and high v1/v2 levels were associated with worse overall survival (p = 0.0045). The prognostic impact of PD-L1 was limited to AML with mutated nucleophosmin and concomitant internal tandem duplications in the FLT3 gene (p less than 0.0001 for this particular AML subgroup).
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19044765
- 003
- CZ-PrNML
- 005
- 20200113081304.0
- 007
- ta
- 008
- 200109s2019 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/ijms20112823 $2 doi
- 035 __
- $a (PubMed)31185600
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Brodská, Barbora $u Institute of Hematology and Blood Transfusion, Prague 128 20, Czech Republic. brodska@uhkt.cz.
- 245 10
- $a High PD-L1 Expression Predicts for Worse Outcome of Leukemia Patients with Concomitant NPM1 and FLT3 Mutations / $c B. Brodská, P. Otevřelová, C. Šálek, O. Fuchs, Z. Gašová, K. Kuželová,
- 520 9_
- $a Compared to solid tumors, the role of PD-L1 in hematological malignancies is less explored, and the knowledge in this area is mostly limited to lymphomas. However, several studies indicated that PD-L1 is also overexpressed in myeloid malignancies. Successful treatment of the acute myeloid leukemia (AML) is likely associated with elimination of the residual disease by the immune system, and possible involvement of PD-L1 in this process remains to be elucidated. We analyzed PD-L1 expression on AML primary cells by flow cytometry and, in parallel, transcript levels were determined for the transcription variants v1 and v2. The ratio of v1/v2 cDNA correlated with the surface protein amount, and high v1/v2 levels were associated with worse overall survival (p = 0.0045). The prognostic impact of PD-L1 was limited to AML with mutated nucleophosmin and concomitant internal tandem duplications in the FLT3 gene (p less than 0.0001 for this particular AML subgroup).
- 650 _2
- $a antigeny CD274 $x krev $x genetika $x metabolismus $7 D060890
- 650 _2
- $a nádorové biomarkery $x krev $x genetika $x metabolismus $7 D014408
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a akutní myeloidní leukemie $x krev $x genetika $7 D015470
- 650 _2
- $a mutace $7 D009154
- 650 _2
- $a jaderné proteiny $x genetika $7 D009687
- 650 _2
- $a messenger RNA $x genetika $x metabolismus $7 D012333
- 650 _2
- $a tyrosinkinasa 3 podobná fms $x genetika $7 D051941
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Otevřelová, Petra $u Institute of Hematology and Blood Transfusion, Prague 128 20, Czech Republic. Petra.Otevrelova@uhkt.cz.
- 700 1_
- $a Šálek, Cyril $u Institute of Hematology and Blood Transfusion, Prague 128 20, Czech Republic. Cyril.Salek@uhkt.cz.
- 700 1_
- $a Fuchs, Ota $u Institute of Hematology and Blood Transfusion, Prague 128 20, Czech Republic. Ota.Fuchs@uhkt.cz.
- 700 1_
- $a Gašová, Zdenka $u Institute of Hematology and Blood Transfusion, Prague 128 20, Czech Republic. Zdenka.Gasova@uhkt.cz.
- 700 1_
- $a Kuželová, Kateřina $u Institute of Hematology and Blood Transfusion, Prague 128 20, Czech Republic. kuzelova@uhkt.cz.
- 773 0_
- $w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 20, č. 11 (2019)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31185600 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200109 $b ABA008
- 991 __
- $a 20200113081636 $b ABA008
- 999 __
- $a ok $b bmc $g 1483034 $s 1083438
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 20 $c 11 $e 20190610 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
- GRA __
- $a grant No 16-30268A and project for conceptual development of the research organization No 00023736. $p Ministerstvo Zdravotnictví Ceské Republiky
- GRA __
- $a NV16-30268A $p MZ0
- LZP __
- $a Pubmed-20200109
